Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 15/20 | 0.40 |
| ▸ | ARG2 | P78540 | 11/20 | 0.40 |
| ▸ | ODC1 | P11926 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10265462 | 0.92 | ARG1 (0.41) | ARG1ARG2ODC1MEN1ALDH1A1 | |
| SCHEMBL894088 | 0.82 | ARG1 (0.63) | ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL895621 | 0.81 | ARG1 (0.61) | ARG1ARG2 | |
| SCHEMBL16309670 | 0.79 | ARG1 (0.46) | ARG1ARG2ODC1MEN1ALDH1A1 | |
| SCHEMBL16309682 | 0.78 | ARG1 (0.39) | ARG1ARG2ODC1 | |
| SCHEMBL10265289 | 0.77 | ARG1 (0.62) | ARG1ARG2ODC1MEN1ALDH1A1 | |
| SCHEMBL894777 | 0.75 | ARG1 (0.65) | ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL894316 | 0.74 | ARG1 (0.63) | ARG1ARG2 | |
| SCHEMBL3256585 | 0.73 | ODC1 (0.50) | ARG1ARG2ODC1MEN1ALDH1A1 | |
| SCHEMBL16309648 | 0.72 | ARG1 (0.72) | ARG1ARG2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170183362-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2017-06-29 | — | — | US | disclosed |
| US-9040703-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140371175-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2014-12-18 | — | — | US | disclosed |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183362-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | ARG1 1/4885ARG2 2/4885ODC1 62/4885 |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | ARG1 1/4885ARG2 2/4885ODC1 62/4885 |
| US-20140371175-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | ARG1 1/4885ARG2 2/4885ODC1 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.